Interpace Biosciences, Inc. Common Stock
IDXG
IDXG was delisted on the 24th of February, 2021.
28 hedge funds and large institutions have $32.9M invested in Interpace Biosciences, Inc. Common Stock in 2014 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 9 increasing their positions, 5 reducing their positions, and 1 closing their positions.
200% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 1
80% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 5
8% more funds holding
Funds holding: 26 → 28 (+2)
5% less capital invested
Capital invested by funds: $34.8M → $32.9M (-$1.83M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KCM
Kennedy Capital Management
St Louis,
Missouri
|
+$65.1K |
| 2 |
HA
Heartland Advisors
Milwaukee,
Wisconsin
|
+$60.9K |
| 3 |
Renaissance Technologies
New York
|
+$24K |
| 4 |
MA
Minerva Advisors
Bala Cynwyd,
Pennsylvania
|
+$15.2K |
| 5 |
U
UBS
Zurich,
Switzerland
|
+$7.84K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RA
Royce & Associates
New York
|
-$344K |
| 2 |
SKK
Shepherd Kaplan Krochuk
Boston,
Massachusetts
|
-$73.4K |
| 3 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$59K |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
-$40.6K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
-$9.23K |
IDXG Hedge Fund Activity: Q2 2014 in Review
28 of the 3,491 institutional investors tracked by Wall St. Rank reported a position in Interpace Biosciences, Inc. Common Stock (IDXG) for Q2 2014, worth a combined $32.9M — down 5.3% from $34.8M a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new IDXG positions and 1 closed out — a net gain of 2 holders — while 9 added to existing stakes and 5 trimmed.
The largest buyer was Kennedy Capital Management, adding an estimated $65.1K. The largest seller was Royce & Associates, cutting an estimated $344K.
- 28 institutional investors held Interpace Biosciences, Inc. Common Stock (IDXG) as of Q2 2014, up from 26 in Q1 2014.
- Funds reported $32.9M of Interpace Biosciences, Inc. Common Stock stock for Q2 2014, down 5.3% quarter-over-quarter.
- 3 funds opened new Interpace Biosciences, Inc. Common Stock positions in Q2 2014 and 1 closed out, a net change of +2 holders.
- The largest Interpace Biosciences, Inc. Common Stock buyer in Q2 2014 was Kennedy Capital Management, an estimated $65.1K added.
- The largest Interpace Biosciences, Inc. Common Stock seller in Q2 2014 was Royce & Associates, an estimated $344K sold.
Based on aggregated 13F filings for Q2 2014.